Nanoparticle Cancer Vaccine Prevents Up to 88% of Tumors in Mice

A nanoparticle cancer vaccine prevented up to 88% of tumors in mice by training the immune system against melanoma, pancreatic cancer and triple-negative breast cancer.

Medicine

Details

Researchers have reported promising preclinical results from a nanoparticle-based cancer vaccine tested in mice. The vaccine is designed to push the immune system to recognize cancer cells and build a stronger response against them. In experiments involving melanoma, pancreatic cancer and triple-negative breast cancer, the approach prevented tumors from taking hold in many vaccinated mice, with results reaching 88% tumor rejection depending on the cancer type. The researchers used nanoparticles that stimulate multiple immune pathways along with cancer-related material, helping immune cells process potential tumor targets and activate tumor-fighting T cells. In the study, the vaccinated mice that rejected tumors also resisted later exposure to cancer cells, suggesting that the treatment generated immune memory. The findings are encouraging because these cancers can be difficult to treat, but the work is still at the animal-testing stage. A result in mice does not establish that the same vaccine will prevent or treat cancer in people. Before human testing, researchers still need additional safety and immune-response studies, manufacturing work, and regulatory review. The longer-term research program is also looking at therapeutic use in animals that already have tumors and at ways to adapt the platform for different cancers. If the approach continues to hold up in later studies, it could become part of a broader effort to make cancer vaccines more practical and widely applicable.

More videos

Up nextThe Chimpanzee That Prepared Rocks for a Future Outburst